Akums FY26 Revenue Rises 5.9%, EBITDA 13%

Akums Drugs & Pharmaceuticals reported FY26 operating revenue of Rs 4,359 cr, up 5.9% YoY, and Adj EBITDA of Rs 522 cr, up 13.3%.
Q4 FY26 revenue reached Rs 1,158 cr (+9.7% YoY) with Adj EBITDA margin improving to 13.1% from 8.9% a year earlier.
Board recommended a final dividend of Rs 1 per share and a special dividend of Rs 2 per share for FY25‑26.
CDMO segment drove growth, with revenue Rs 952 cr (+13.3% YoY) and EBITDA margin 14.4% vs 10.6% prior year.